-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
Research Update: Clinical Investigation
-
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
Research Update: Clinical Investigation
-
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
Research Update: Clinical Investigation
-
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
Research Update: Clinical Investigation
-
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
Research Update: Clinical Investigation
-
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
Research Update: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia
Meenakshi Devidas, James R Anderson
Clinical Trail Methodology: Clinical Investigation